Jazz Pharmaceuticals plc (JAZZ)
NASDAQ: JAZZ · Real-Time Price · USD
182.58
+4.03 (2.26%)
Mar 16, 2026, 10:51 AM EDT - Market open
| Period Ending | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Neuroscience | 2.88B | 2.82B | 2.75B | 2.72B | 2.70B | 2.66B | 2.63B | 2.64B | |||||||||||||
| Neuroscience Growth | 6.68% | 6.01% | 4.40% | 3.25% | -0.35% | -3.68% | -5.92% | -5.85% | |||||||||||||
| Oncology | 1.13B | 1.08B | 1.08B | 1.08B | 1.11B | 1.09B | 1.07B | 1.04B | |||||||||||||
| Oncology Growth | 1.56% | -0.93% | 1.04% | 3.77% | 9.47% | 13.26% | 15.16% | 15.23% |
| Period Ending | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rylaze Enrylaze | 402.92M | 396.25M | 395.16M | 402.33M | 410.85M | 411.11M | 417.19M | 411.05M | - | - | - | - | - | - | |||||||
| Rylaze Enrylaze Growth | -1.93% | -3.61% | -5.28% | -2.12% | 4.22% | 10.08% | 21.95% | 31.17% | - | - | - | - | - | - | |||||||
| Zepzelca | 307.31M | 295.20M | 301.75M | 308.25M | 320.32M | 316.00M | 308.15M | 297.45M | - | - | |||||||||||
| Zepzelca Growth | -4.06% | -6.58% | -2.08% | 3.63% | 10.63% | 9.92% | 10.13% | 7.09% | - | - | |||||||||||
| Defitellio Defibtrotide | 199.39M | 198.17M | 212.24M | 209.55M | 216.57M | 210.00M | 191.91M | 192.60M | |||||||||||||
| Defitellio Defibtrotide Growth | -7.93% | -5.63% | 10.59% | 8.80% | 17.70% | 20.99% | 9.48% | 4.74% | |||||||||||||
| Vyxeos | 146.71M | 165.23M | 161.96M | 160.12M | 162.60M | 156.26M | 151.77M | 142.82M | |||||||||||||
| Vyxeos Growth | -9.77% | 5.74% | 6.71% | 12.11% | 10.24% | 19.42% | 15.78% | 9.09% | |||||||||||||
| Erwinaze | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 146.10M | 150.47M | 147.14M |
| Period Ending | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Xywav | 1.66B | 1.59B | 1.55B | 1.50B | 1.47B | 1.41B | 1.35B | 1.31B | - | - | - | ||||||||||
| Xywav Growth | 12.48% | 13.00% | 14.58% | 14.67% | 15.73% | 15.77% | 18.46% | 24.80% | - | - | - | ||||||||||
| Epidiolex | 1.06B | 1.05B | 996.07M | 991.44M | 972.42M | 938.00M | 900.15M | 855.28M | - | - | - | - | - | ||||||||
| Epidiolex Growth | 8.92% | 11.63% | 10.66% | 15.92% | 15.02% | 15.54% | 13.32% | 11.45% | - | - | - | - | - | ||||||||
| Xyrem | 146.03M | 157.54M | 179.99M | 206.83M | 233.82M | 291.25M | 358.24M | 455.83M | |||||||||||||
| Xyrem Growth | -37.54% | -45.91% | -49.76% | -54.63% | -58.96% | -59.01% | -57.42% | -52.07% | |||||||||||||
| Sunosi | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 63.03M | 62.19M | 57.91M | 51.70M | 41.56M | 38.02M | 28.33M |
| Sunosi Growth | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 51.65% | 63.58% | 104.40% | - | - | - | - |
| Sativex | 16.28M | 19.95M | 19.78M | 21.55M | 18.88M | 18.84M | 18.88M | 15.31M | - | - | - | - | - | ||||||||
| Sativex Growth | -13.77% | 5.87% | 4.76% | 40.80% | -4.02% | -2.13% | 5.81% | -20.21% | - | - | - | - | - |
Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.